Skip to main navigation

Investors

News Archive
Past Events and Presentations
Stock History

News Archive

News Archive

Items Per Page

Year

Feb 19, 2009

Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008

Feb 19, 2009

Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell

Feb 16, 2009

Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast

Jan 30, 2009

Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER

Jan 29, 2009

Mylan Declares Quarterly Preferred Stock Dividend

Jan 28, 2009

Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD

Jan 23, 2009

Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg

Jan 12, 2009

U.S. Patent and Trademark Office Issues Mylan's Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution

Dec 30, 2008

Mylan's Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules

Dec 12, 2008

Mylan Announces Move to NASDAQ Stock Market

Pagination

First page
Previous page
…
Page 87
Page 88
Page 89
Page 90
Current page 91
Page 92
Page 93
Page 94
Page 95
…
Next page
Last page

Share

Utility Nav

Privacy Statement
Terms and Conditions

©2025 Mylan N.V. All rights reserved. The Mylan logo is a registered trademark of Mylan Inc.